About GenapSys
GenapSys is a company based in Redwood City (United States) founded in 2010. GenapSys has raised $313.03 million across 9 funding rounds from investors including HHS, Farallon Capital Management and Oxford Finance. The company has 60 employees as of December 31, 2022. GenapSys operates in a competitive market with competitors including Cepheid, Nanopore, PacBio, Fluidigm and Omniome, among others.
- Headquarter Redwood City, United States
- Employees 60 as on 31 Dec, 2022
-
Sectors
Retail
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Genapsys
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$313.03 M (USD)
in 9 rounds
-
Latest Funding Round
$70 M (USD), Series D
Mar 01, 2021
-
Investors
HHS
& 8 more
-
Employee Count
60
as on Dec 31, 2022
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of GenapSys
Unlock access to complete
Unlock access to complete
Funding Insights of GenapSys
GenapSys has successfully raised a total of $313.03M across 9 strategic funding rounds. The most recent funding activity was a Series D round of $70 million completed in March 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in GenapSys
GenapSys has secured backing from 9 investors, including venture fund, institutional, and angel investors. Prominent investors backing the company include HHS, Farallon Capital Management and Oxford Finance.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Multiple investment strategies are pursued by this hedge fund.
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked | |
|
Venture debt firm focused on the life sciences sector
|
Locked | Locked | Locked |
Investor details for GenapSys
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by GenapSys
Investment portfolio details for GenapSys
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - GenapSys
Detailed financials for GenapSys
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Genapsys Comparisons
Peer comparison for GenapSys
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of GenapSys
GenapSys operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Cepheid, Nanopore, PacBio, Fluidigm and Omniome, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of molecular diagnostic testing solutions
|
|
| Locked | Locked | Locked |
Nanopore-based electronic systems for single-molecule analysis are developed.
|
|
| Locked | Locked | Locked |
Instrument systems and software for single-molecule real-time sequencing are developed.
|
|
| Locked | Locked | Locked |
Instruments for life sciences research and applications are developed.
|
|
| Locked | Locked | Locked |
Genome sequencing platform is provided for clinical diagnostics.
|
|
| Locked | Locked | Locked |
DNA sequencing platform for human genome analysis is developed.
|
Detailed competitors of GenapSys
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Genapsys
Complete news archive for GenapSys
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about GenapSys
GenapSys was founded in 2010 and raised its 1st funding round 2 years after it was founded.
GenapSys is headquartered in Redwood City, United States. It is registered at Redwood City, California, United States.
GenapSys is a funded company, having raised a total of $313.03M across 9 funding rounds to date.
As of Dec 31, 2022, the latest employee count at GenapSys is 60.
GenapSys was founded in 2010 and is based in Redwood City, United States. DNA sequencing technologies are offered by the company for applied genomic testing and medical sequencing within the biotechnology sector. A chip-based portable system called Gene Electronic Nano-Integrated Ultra-Sensitive has been developed for these purposes. Operations cover research, diagnostics, drug development, agriculture, forensics, and personal genomics.
GenapSys has 9 investors. Key investors include HHS, Farallon Capital Management, Oxford Finance, Soleus Capital, and Foresite Capital.